Loading...
XSTO
BIOVIC B
Market cap7mUSD
Jul 10, Last price  
0.41SEK
1D
7.37%
1Q
6.25%
IPO
-96.81%
Name

Biovica International AB

Chart & Performance

D1W1MN
XSTO:BIOVIC B chart
P/E
—
P/S
5.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
50.36%
Rev. gr., 5y
45.15%
Revenues
13m
+55.24%
4,045,026459,0002,432,000632,0002,723,0003,005,0001,671,0002,077,0002,045,0003,384,0007,290,0008,619,00013,380,000
Net income
-70m
L-20.27%
-5,371,659-7,043,000-5,031,000-14,857,000-18,064,000-21,556,000-30,318,000-39,483,000-60,003,000-110,492,000-124,823,000-87,624,000-69,860,000
CFO
-63m
L-26.43%
0922,000-9,385,000-11,090,000-14,882,000-17,966,000-24,780,000-34,409,000-52,126,000-94,640,000-114,575,000-85,367,000-62,806,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
URL
https://biovica.com/
IPO date
Mar 29, 2017
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT